Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity

[Display omitted] •Two new adjuvants were designed and prepared: Chi-C48/80 NP and Chi/Alg-C48/80 NP.•Chi NP but not Chi/Alg NP revealed to be a mast cell activator.•Chi-C48/80 NP increased ovalbumin nasal residence time.•Both C48/80 loaded NPs elicited high titers of neutralizing Abs against anthra...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmaceutics and biopharmaceutics 2015-06, Vol.93, p.149-164
Hauptverfasser: Bento, D., Staats, H.F., Gonçalves, T., Borges, O.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •Two new adjuvants were designed and prepared: Chi-C48/80 NP and Chi/Alg-C48/80 NP.•Chi NP but not Chi/Alg NP revealed to be a mast cell activator.•Chi-C48/80 NP increased ovalbumin nasal residence time.•Both C48/80 loaded NPs elicited high titers of neutralizing Abs against anthrax lethal toxin.•Nasal immunization with Chi-C48/80 NP induced a strong PA-specific mucosal immunity. In a time in which mucosal vaccines development has been delayed by the lack of safe and effective mucosal adjuvants, the combination of adjuvants has started to be explored as a strategy to obtain potent vaccine formulations. This study describes a novel adjuvant combination as an effective approach for a nasal vaccine – the association of the mast cell activator compound 48/80 with chitosan based nanoparticles. It was hypothesized that mucoadhesive nanoparticles would promote the cellular uptake and prolong the antigen residence time on nasal cavity. Simultaneously, mast cell activation would promote a local microenvironment favorable to the development of an immune response. To test this hypothesis, two different C48/80 loaded nanoparticles (NPs) were prepared: Chitosan-C48/80 NP (Chi-C48/80 NP) and Chitosan/Alginate-C48/80 NP (Chi/Alg-C48/80 NP). The potential as a vaccine adjuvant of the two delivery systems was evaluated and directly compared. Both formulations had a mean size near 500nm and a positive charge; however, Chi-C48/80 NP was a more effective adjuvant delivery system when compared with Chi/Alg-C48/80 NP or C48/80 alone. Chi-C48/80 NP activated mast cells at a greater extent, were better internalized by antigen presenting cells than Chi/Alg-C48/80 NP and successfully enhanced the nasal residence time of a model antigen. Superiority of Chi-C48/80 NP as adjuvant was also observed in vivo. Therefore, nasal immunization of mice with Bacillus anthracis protective antigen (PA) adsorbed on Chi-C48/80 NP elicited high levels of serum anti-PA neutralizing antibodies and a more balanced Th1/Th2 profile than C48/80 in solution or Chi/Alg-C48/80 NP. The incorporation of C48/80 within Chi NP also promoted a mucosal immunity greater than all the other adjuvanted groups tested, showing that the combination of a mast cell activator and chitosan NP could be a promising strategy for nasal immunization.
ISSN:0939-6411
1873-3441
DOI:10.1016/j.ejpb.2015.03.024